Xeris Biopharma Holdings Statistics
Total Valuation
XERS has a market cap or net worth of $350.63 million. The enterprise value is $531.97 million.
| Market Cap | 350.63M |
| Enterprise Value | 531.97M |
Important Dates
The next confirmed earnings date is Thursday, August 8, 2024, before market open.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
XERS has 148.26 million shares outstanding. The number of shares has increased by 2.46% in one year.
| Shares Outstanding | 148.26M |
| Shares Change (YoY) | +2.46% |
| Shares Change (QoQ) | +1.73% |
| Owned by Insiders (%) | 2.69% |
| Owned by Institutions (%) | 41.94% |
| Float | 143.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.05 |
| Forward PS | 1.74 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.37
| Current Ratio | 2.37 |
| Quick Ratio | 1.71 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.38 |
Financial Efficiency
Return on equity (ROE) is -16,662.60% and return on invested capital (ROIC) is -17.33%.
| Return on Equity (ROE) | -16,662.60% |
| Return on Assets (ROA) | -19.60% |
| Return on Capital (ROIC) | -17.33% |
| Revenue Per Employee | $454,525 |
| Profits Per Employee | -$170,825 |
| Employee Count | 377 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 0.84 |
Taxes
| Income Tax | -942,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.75% in the last 52 weeks. The beta is 1.29, so XERS's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | -10.75% |
| 50-Day Moving Average | 2.16 |
| 200-Day Moving Average | 2.16 |
| Relative Strength Index (RSI) | 57.03 |
| Average Volume (20 Days) | 1,203,666 |
Short Selling Information
The latest short interest is 11.00 million, so 7.42% of the outstanding shares have been sold short.
| Short Interest | 11.00M |
| Short Previous Month | 11.09M |
| Short % of Shares Out | 7.42% |
| Short % of Float | 7.65% |
| Short Ratio (days to cover) | 6.95 |
Income Statement
In the last 12 months, XERS had revenue of $171.36 million and -$64.40 million in losses. Loss per share was -$0.46.
| Revenue | 171.36M |
| Gross Profit | 142.06M |
| Operating Income | -44.98M |
| Pretax Income | -65.34M |
| Net Income | -64.40M |
| EBITDA | -24.73M |
| EBIT | -37.92M |
| Loss Per Share | -$0.46 |
Balance Sheet
The company has $87.35 million in cash and $268.70 million in debt, giving a net cash position of -$181.34 million or -$1.22 per share.
| Cash & Cash Equivalents | 87.35M |
| Total Debt | 268.70M |
| Net Cash | -181.34M |
| Net Cash Per Share | -$1.22 |
| Equity (Book Value) | -9.18M |
| Book Value Per Share | -0.06 |
| Working Capital | 100.20M |
Cash Flow
In the last 12 months, operating cash flow was -$41.19 million and capital expenditures -$2.19 million, giving a free cash flow of -$43.38 million.
| Operating Cash Flow | -41.19M |
| Capital Expenditures | -2.19M |
| Free Cash Flow | -43.38M |
| FCF Per Share | -$0.31 |
Margins
Gross margin is 82.90%, with operating and profit margins of -26.25% and -37.58%.
| Gross Margin | 82.90% |
| Operating Margin | -26.25% |
| Pretax Margin | -38.13% |
| Profit Margin | -37.58% |
| EBITDA Margin | -14.43% |
| EBIT Margin | -22.13% |
| FCF Margin | -25.31% |
Dividends & Yields
XERS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.46% |
| Shareholder Yield | -2.46% |
| Earnings Yield | -18.37% |
| FCF Yield | -12.37% |
Analyst Forecast
The average price target for XERS is $4.63, which is 95.77% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.63 |
| Price Target Difference | 95.77% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 17.30% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | Oct 6, 2021 |
| Split Type | n/a |
| Split Ratio | 1:1 |
Scores
XERS has an Altman Z-Score of -1.54 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.54 |
| Piotroski F-Score | 4 |